Literature DB >> 15596572

Short- and long-term incidence of stroke in white-coat hypertension.

Paolo Verdecchia1, Gian Paolo Reboldi, Fabio Angeli, Giuseppe Schillaci, Joseph E Schwartz, Thomas G Pickering, Yutaka Imai, Takayoshi Ohkubo, Kazuomi Kario.   

Abstract

White-coat hypertension (WCH) has been associated with a low risk for stroke, but long-term data are scanty. We analyzed individual data from 4 prospective cohort studies from the United States, Italy, and Japan that used comparable methodology for 24-hour noninvasive ambulatory blood pressure monitoring (ABPM). Overall, 4406 subjects with essential hypertension and 1549 healthy normotensive controls who were untreated at the time of initial ABPM were followed for a median of 5.4 years up to censoring or occurrence of a first stroke. At entry, mean age of subjects was 56 years (range 18 to 97). Prevalence of WCH was 9%. During follow-up, there were 213 new cases of stroke. Stroke rate (x100 person years) was 0.35 in the normotensive group, 0.59 in the WCH group, and 0.65 in the group with ambulatory hypertension. In a multivariate analysis, the adjusted hazard ratio for stroke was 1.15 (95% confidence interval [CI], 0.61 to 2.16) in the WCH group (P=0.66) and 2.01 (95% CI, 1.31 to 3.08) in the ambulatory hypertension group (P=0.001) compared with the normotensive group. After the sixth year of follow-up, the incidence of stroke tended to increase in the WCH group, and the corresponding hazard curve crossed that of the ambulatory hypertension group by the ninth year of follow-up. In conclusion, WCH was not associated with a definitely increased risk of stroke during the total follow-up period. However, WCH might not be a benign condition for stroke in the long term.

Entities:  

Mesh:

Year:  2004        PMID: 15596572     DOI: 10.1161/01.HYP.0000151623.49780.89

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  57 in total

1.  Clinical trials report. White-coat hypertension and stroke incidence.

Authors:  Domenic A Sica
Journal:  Curr Hypertens Rep       Date:  2005-08       Impact factor: 5.369

Review 2.  Ambulatory blood pressure monitoring: from old concepts to novel insights.

Authors:  Mehmet Kanbay; Kultigin Turkmen; Tevfik Ecder; Adrian Covic
Journal:  Int Urol Nephrol       Date:  2011-07-06       Impact factor: 2.370

Review 3.  Ambulatory blood pressure improves prediction of cardiovascular risk: implications for better antihypertensive management.

Authors:  Lawrence R Krakoff
Journal:  Curr Atheroscler Rep       Date:  2013-04       Impact factor: 5.113

4.  How many clinic BP readings are needed to predict cardiovascular events as accurately as ambulatory BP monitoring?

Authors:  K Eguchi; S Hoshide; K Shimada; K Kario
Journal:  J Hum Hypertens       Date:  2014-02-20       Impact factor: 3.012

5.  Clinical implications of ambulatory and home blood pressure monitoring.

Authors:  Soon-Gil Kim
Journal:  Korean Circ J       Date:  2010-09-30       Impact factor: 3.243

Review 6.  Ambulatory blood pressure monitoring: a versatile tool for evaluating and managing hypertension in children.

Authors:  Alisa A Acosta; Karen L McNiece
Journal:  Pediatr Nephrol       Date:  2008-02-23       Impact factor: 3.714

7.  Can an Emotional Reaction Mimicking White-coat Hypertension Cause Hypertensive Crisis and Cardiac Failure?

Authors:  Francesco Salvo; Francesca Camardella; Cinzia Vallo; Paolo Fogliacco; Andrea Riccardo Errani; Michele Berardi; Monica Albano; Vito Meinero; Carlo Lorenzo Muzzulini; Alberto Morganti
Journal:  High Blood Press Cardiovasc Prev       Date:  2016-01-05

Review 8.  Pharmacologic Management of Pediatric Hypertension.

Authors:  Jason Misurac; Kristen R Nichols; Amy C Wilson
Journal:  Paediatr Drugs       Date:  2016-02       Impact factor: 3.022

9.  The relationship between soluble CD40 ligand level and atherosclerosis in white-coat hypertension.

Authors:  Yu-Qing Huang; L I Jie; Ji-Yan Chen; Song-Tao Tang; Cheng Huang; Ying-Qing Feng
Journal:  J Hum Hypertens       Date:  2017-11-21       Impact factor: 3.012

Review 10.  White-coat hypertension should not be treated in subjects with diabetes.

Authors:  Michael Bursztyn; Iddo Z Ben-Dov
Journal:  Diabetes Care       Date:  2009-11       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.